Showing results 2 to 2 of 2
< previous
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma Journal:Clinical Cancer Research | 2018 | 50 |